Emcure Pharmaceuticals Limited responded to an exchange query regarding a significant increase in its share price and trading volume observed recently. The company clarified on March 10, 2026, that the movement is entirely market-driven and beyond the company’s control. Emcure affirmed that there is currently no undisclosed price-sensitive event or information that requires mandatory disclosure under prevailing listing regulations.
Response to Exchange Query
Emcure Pharmaceuticals Limited issued a formal clarification on March 10, 2026, addressing queries raised by the stock exchange concerning a noticeable surge in the trading volume and price of its shares. The reference for this inquiry was dated March 10, 2026.
Market-Driven Observation
The management stated clearly that the observed increase in the price and volume of the Company’s shares is purely market-driven. The Company explicitly confirmed that it has no control over these fluctuations in market activity.
Disclosure Confirmation
Furthermore, Emcure confirmed that, as of the date of the letter, there is no event or information currently in existence that necessitates disclosure under the framework governing Listing Obligations and Disclosure Requirements. The Company assured stakeholders that it remains fully aware of its ongoing disclosure obligations and will continue to ensure the timely release of any material event or information as and when it arises in the future.
The clarification was formally signed by Amruta Yangalwar, Company Secretary & Compliance Officer, under Membership Number A25687.
Source: BSE
